Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Abivax announced full exercise of the underwriters’ over-allotment option, adding 960,000 ADSs and increasing gross offering proceeds to about $920.0M (€807.4M). Total ADSs issued after the option exercise will be 7,360,000 ADSs (gross), with estimated net proceeds of approximately $874.1M (€767.1M) after underwriting commissions and offering expenses. Net proceeds are earmarked for US commercialization expenses for obefazimod and further Phase 3 R&D for ulcerative colitis and Crohn’s disease, with any remainder for general corporate purposes.

Analysis

The key market mechanism is not the capital raise itself but the reset in financing risk: this size, fully covered print materially lowers the probability of a forced second deal before the next clinical catalyst. For a pre-revenue biotech, that matters because the equity story is almost always a race between trial timing and runway; removing the near-term liquidity overhang can compress the discount rate investors apply to the pipeline, even if the stock initially trades like a diluted asset.

Near term, though, the supply overhang is still real. Once the greenshoe is absorbed and the deal settles, the marginal buyer has to decide whether to own binary phase-3 risk without the excuse of balance-sheet stress; that usually means choppy trading rather than an immediate rerate. The bigger second-order winner is management’s negotiating leverage: with cash in hand, they can avoid signing a value-destructive partnership from weakness and may be able to wait for cleaner clinical data before monetizing ex-U.S. or combination rights.

The contrarian read is that the market should not treat this as a bullish fundamental update by itself. Full take-up at an orderly price suggests demand existed, but it does not validate the drug; the thesis still lives or dies on upcoming efficacy/safety readouts and whether burn accelerates faster than expected. If the shares cannot hold above the offer level after settlement, that is a signal investors are valuing runway more than probability of success.

Key Decisions for Investors

• Do not chase ABVX immediately into settlement; wait 3-5 trading days for post-deal digestion. If the stock holds above the offering price on normal volume, a tactical long becomes viable with a 10-15% upside target into the next catalyst and an 8-10% stop below the deal level.
• Use any post-close weakness in ABVX as a runway-de-risking entry only if volume stabilizes and there is no new clinical delay. The setup is more about avoiding a financing overhang than expressing conviction in efficacy.
• Pair trade: long ABVX / short XBI for 1-3 months if ABVX shows relative strength after the close. The idea is idiosyncratic balance-sheet de-risking versus generic biotech beta; exit if ABVX loses the offer price or XBI enters a broad sector rally.
• No aggressive long-dated options recommendation yet; wait for a clearer phase-3 readout window. Without a dated clinical catalyst, optionality is expensive relative to the information content.
• Set a watch item for any partnership or BD disclosure over the next 6-12 months. If management converts this cash into a non-dilutive deal or defers commercialization spend, the rerating potential is materially higher; absent that, this remains a funding bridge, not a de-risked asset.